Showing 1 - 1 of 1
Virtually every aspect of the 340B drug discount program has been evaluated except its effectiveness at improving healthcare access for medically underserved populations. This paper seeks to fill this information gap by using federal data to measure changes in the ability of impoverished and...
Persistent link: https://www.econbiz.de/10012908050